Roivant's Mosliciguat Scores Strong Phase 2 in PH-ILD — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Mosliciguat, Roivant's pipeline drug, achieved strong efficacy in a Phase 2 study of PH-ILD (pulmonary hypertension associated with interstitial lung disease), per STAT+.
- Roivant could see its financial health bolstered by mosliciguat becoming a second blockbuster medicine if the PH-ILD data hold up, the author writes.
- STAT+ characterizes Roivant as one of the savviest dealmakers in biotech and singles out mosliciguat's origins as a notable facet of the company's pipeline.
- The author argues the Phase 2 results could open up a new way to treat PH-ILD, a serious lung disease.
Why it matters: If mosliciguat becomes Roivant's second blockbuster, the biotech gains revenue and credibility for its dealmaking strategy. For PH-ILD patients with limited treatment options, the Phase 2 efficacy represents concrete evidence of a potential new therapy in this disease.
Ask SkimNews
